| Title: | A gene-level methylome-wide association analysis identifies novel Alzheimer's disease genes |
| Journal: | Bioinformatics |
| Published: | 1 Feb 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/33523132/ |
| DOI: | https://doi.org/10.1093/bioinformatics/btab045 |
Publication 3263
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Motivation: Transcriptome-wide association studies (TWAS) have successfully facilitated the dis13 covery of novel genetic risk loci for many complex traits, including late-onset Alzheimer s disease (AD). However, most existing TWAS methods rely only on gene expression and ignore epige15 netic modification (i.e., DNA methylation) and functional regulatory information (i.e., enhancer16 promoter interactions), both of which contribute significantly to the genetic basis of AD.Results: This motivates us to develop a novel gene-level association testing method that inte18 grates genetically regulated DNA methylation and enhancer-target gene pairs with genome-wideassociation study (GWAS) summary results. Through simulations, we show that our approach, referred to as the CMO (cross methylome omnibus) test, yielded well controlled type I error rates and achieved much higher statistical power than competing methods under a wide range of scenar22 ios. Furthermore, compared with TWAS, CMO identified an average of 124% more associations when analyzing several brain imaging-related GWAS results. By analyzing to date the largest AD GWAS of 71,880 cases and 383,378 controls, CMO identified six novel loci for AD, which have been ignored by competing methods.
1 Author
- Wu C et al.
1 Application
| Application ID | Title |
|---|---|
| 48240 | Integrative analysis of UK Biobank and other genetic and genomic datasets for complex disease detection and prevention |
Enabling scientific discoveries that improve human health